Apellis Pharmaceuticals Inc — Cash Flow (NASDAQ:APLS) | MetaTrader

Open full chart

Financials

Overview 明細書 Statistics Dividends

Quarterly Annual

Cash from operating activities 160.49 M563.13 M513.75 M594.74 M87.87 M45.33 M 45.33 M Cash from investing activities 316.99 M247.62 M59.89 M674 K403 K313 K 313 K Cash from financing activities 692.18 M392.24 M365.66 M394.5 M149.24 M8.88 M 8.88 M Free cash flow 155.07 M562.02 M512.22 M593.96 M87.46 M45.01 M 45.01 M

ニュース

Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y

H.C. Wainwrightがアペリス株の目標株価を引き上げ、Syfovre見通しを評価

H.C. Wainwright raises Apellis stock price target on Syfovre outlook

Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript

【決算速報】アペリス・ファーマシューティカルズ、売上高は予想を上回り、利益は予想を上回る結果に

Apellis Pharma earnings beat by $0.85, revenue topped estimates

Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates

Apellis 2025年第4四半期決算:二製品の成長と収益化への道筋

Apellis Q4 2025 slides: dual product growth, path to profitability

Apellis Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:APLS) 2026-02-24

アペリス決算発表控える:新たな腎臓病治療薬が成長の勢いを取り戻せるか

Apellis earnings on deck: Can new kidney drug revive growth momentum?